01 — At a Glance
They Make Holes in Walls. But Also Revolutionary Things In Them.
- 52-Week High / Low₹204 / ₹110
- Q3 FY26 Revenue₹192 Cr
- Q3 FY26 PAT₹20 Cr
- TTM EPS₹3.78
- Annualised EPS (9M Avg × 4/3)₹3.75
- Book Value / Share₹37.5
- Price to Book3.12x
- ROCE16.5%
- ROE (3yr avg)18.5%
- Debt to Equity0.18x
Flash Summary: Standard Engineering Technology just posted Q3 FY26 revenue of ₹192 crore (+37% YoY) and PAT of ₹20 crore (+28% QoQ). But the stock is down 24.7% in the last year. Why? Because investors saw margin compression from 18.6% to 15.1%, panicked, and forgot to read the footnotes where management explains it’s just export delays. Also, they renamed the company, bought two businesses, and are launching conductivity-lining glass reactors in 2027. The market hates surprises and transition stories. This stock is basically a short on impatience.
02 — Introduction
The Invisible Giant That Makes Pharma’s Most Expensive Container
Picture this: you’re a pharmaceutical company. You need to synthesize a molecule that reacts at 200°C, requires pH control to the decimal, and will corrode the living daylights out of any stainless steel or inconel vessel. You call Standard Engineering Technology. They build you a glass-lined reactor — essentially a stainless steel tank with a thin, ultra-hard glass coating on the inside. Think of it as a thermos bottle for chemical synthesis.
Glass-lined equipment is the unsung royalty of pharma manufacturing. It’s in every CDMO facility, every regulated API plant, every chemical synthesis unit. And until recently, this Hyderabad-based company was “Standard Glass Lining Technology.” They made reactors, heat exchangers, dryers, filters. Boring. Mission-critical. Profitable. Very Indian.
Then, in February 2026, they rebranded to “Standard Engineering Technology.” Translation: they’re no longer just a product vendor. They’re now positioning themselves as a full-stack engineering solutions provider — concept-to-commissioning. They bought Scigenics (bioprocess/fermentation systems). They bought 51% of C2C Engineering (a 20-year-old engineering firm). They’re launching glass-lined heat exchangers with a Japanese partner. They’ve opened a US subsidiary. The market’s response: sell everything and ask questions later. Stock down 25% in a year. P/E at 30.9x. Book value being trampled. Welcome to transition-story chaos.
Q3 Concall Reality Check (Feb 2026): Management was crystal clear: “This is not a departure from glass lining. It is an expansion of our identity.” The company is deliberately positioning for larger, higher-margin turnkey plant projects. Orders are coming in for 200 glass-lined heat exchangers already. USD 3.5 million in exports were delayed in Q3 due to documentation from the name change — but ready to ship in Q4. This explains the margin miss. The market didn’t listen. Typical.
03 — Business Model: WTF Do They Even Make?
Glass-Lined Reactors Are To Pharma What Cement Is To India.
Standard Engineering Technology manufactures six categories of precision engineering equipment for pharma and chemical sectors. Glass-lined reactors (AE, BE, CE types, capacity 30L to 250,000L) are the flagship. But they also make stainless steel reactors, nickel alloy reactors, heat exchangers, agitated filter dryers (ANFDs), rotary dryers, vacuum systems, PTFE-lined pipes, and — newly — bioprocess/fermentation systems via Scigenics. They also offer turnkey plant execution and engineering.
The revenue bifurcation (9M FY26): Reaction Systems = 39.9%, Plant & Engineering Services = 33.3%, Storage/Separation/Drying Systems = 6.8%. Geographically: Domestic 93%, Exports 7% (but growing). By customer type: Pharma 72%, Chemicals 15.7%, Others 12.3%. The top 10 customers contribute 38% of revenue. The top 20 contribute 54%. This is a concentrated customer base — high switching costs, long-term relationships (13 of top 20 customers have 3+ year relationships), recurring business.
The company operates nine manufacturing facilities with >500,000 sq. ft. of built-up area. Capacity: 300–350 equipment units per month, 100 reactors/month, 30 ANFDs/month, 9,000 PTFE-lined pipes/month. In Q3, they shipped ₹192 crore in quarterly revenue. The story isn’t just about making glass reactors — it’s about becoming the single-point vendor for entire pharmaceutical manufacturing plants. That’s where the margin expansion is.
Glass-Lined Reactors39.9%of revenue
Plant & Eng. Services33.3%of revenue
Drying & Storage6.8%of revenue
9 Manufacturing Facilities500K+ sq.ftBuilt-up area
The conductivity glass-lined reactor is the real differentiator. Most glass-lined reactors are electrically insulating. In certain pharma synthesis (especially amino acid chains and API manufacturing), static buildup can cause explosions or side reactions. SETL’s new conductivity-lining allows controlled grounding and safe synthesis. Hetero, Sun Pharma, Laurus Labs are already using prototypes. Commercial launch: April 2027. This is a genuine moat. Not revolutionary. But not nothing either.
04 — Financials Overview
Q3 FY26: The Numbers Look Good Until You Check The Margins.
Result type: Quarterly Results | Q3 FY26 EPS: ₹0.96 | Avg Q1–Q3 EPS: (0.81+1.07+0.96)/3 = ₹0.95 | Annualised EPS: ₹3.80 (vs TTM: ₹3.78)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 192 | 140 | 183 | +36.7% | +4.9% |
| EBITDA | 29 | 26 | 29 | +11.5% | -0.0% |
| EBITDA Margin % | 15.1% | 18.6% | 15.8% | -350 bps | -70 bps |
| PAT | 20 | 16 | 20 | +28.0% | +0.0% |
| EPS (₹) | 0.96 | 0.81 | 1.01 | +18.5% | -4.9% |
The Margin Panic Explained: EBITDA margin dropped from 18.6% (Q3 FY25) to 15.1% (Q3 FY26). Investors saw this and concluded the business was deteriorating. Spoiler: it wasn’t. Management explained on the concall that USD 3.5 million in exports were held up in Q3 due to new company name documentation delays. These exports are “ready to dispatch” and will hit Q4 revenue. Exports typically carry higher margins than domestic business. Additionally, the company hired at “high levels” to enter new end-user verticals and consumed more consumables for project work. This is investment spending, not operational decay. Q4 should see margin recovery as exports ship.
💬 If exports ship in Q4 as promised and margins rebound, would you revise your view on SETL? Or do you think the margin miss was a warning sign about project execution? Drop your thoughts.
05 — Valuation: Fair Value Range
₹117 Per Share: Are You Catching A Falling Knife Or A Discount Opportunity?
